Suppr超能文献

环磷酰胺在临时口服混悬液中的稳定性。

Stability of cyclophosphamide in extemporaneous oral suspensions.

机构信息

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

Ann Pharmacother. 2010 Feb;44(2):295-301. doi: 10.1345/aph.1M578. Epub 2010 Jan 26.

Abstract

BACKGROUND

Cyclophosphamide, an alkylating agent, is widely used for the treatment of many adult and pediatric malignancies. The stability of cyclophosphamide in aqueous- and methylcellulose-based oral suspending vehicles is currently unknown.

OBJECTIVE

To develop and validate a stability-indicating high-performance liquid chromatography (HPLC) method to measure cyclophosphamide concentrations in simple syrup and Ora-Plus, and assess the 56-day chemical stability and physical appearance of cyclophosphamide in these suspensions at both room temperature (22 degrees C) and 4 degrees C.

METHODS

The intravenous formulation of cyclophosphamide was diluted to 20 mg/mL in NaCl 0.9%, compounded 1:1 with either suspending vehicle, and stored in the dark in 3-mL amber polypropylene oral syringes at 4 degrees C and 22 degrees C. Aliquots from each syringe were obtained on days 0, 3, 7, 14, 21, 28, 35, 42, 49, and 56 and assayed using the validated stability-indicating HPLC-UV method. A C18 analytical column was used to separate cyclophosphamide from the internal standard, ifosfamide, with a mobile phase of 21% acetonitrile in 79% sodium phosphate buffer. The suspension was examined for odor change, visually examined under normal fluorescent light for color change, and examined under a light microscope for evidence of microbial growth.

RESULTS

Samples of cyclophosphamide in both simple syrup and Ora-Plus were stable when kept at 4 degrees C for at least 56 days. At room temperature, cyclophosphamide in simple syrup and Ora-Plus had a shelf life of 8 and 3 days, respectively. No changes in color or odor or evidence of microbial growth were observed.

CONCLUSIONS

Cyclophosphamide can be extemporaneously prepared in simple syrup or Ora-Plus and stored for at least 2 months under refrigeration without significant degradation.

摘要

背景

环磷酰胺是一种烷化剂,广泛用于治疗许多成人和儿科恶性肿瘤。环磷酰胺在水基和甲基纤维素口服混悬液中的稳定性目前尚不清楚。

目的

开发和验证一种高效液相色谱(HPLC)法,用于测量糖浆和 Ora-Plus 中环磷酰胺的浓度,并评估环磷酰胺在这两种混悬液中的化学稳定性和外观,在 22°C(室温)和 4°C 下,分别储存 56 天。

方法

将环磷酰胺的静脉制剂用 0.9%氯化钠稀释至 20mg/mL,与每种混悬液以 1:1 的比例混合,分别储存在 3-mL 琥珀色聚丙烯口服注射器中,置于 4°C 和 22°C 的暗处。在第 0、3、7、14、21、28、35、42、49 和 56 天,从每个注射器中取出等分试样,并用经过验证的稳定性指示 HPLC-UV 法进行测定。用 C18 分析柱将环磷酰胺与内标异环磷酰胺分离,流动相为 21%乙腈在 79%磷酸钠缓冲液中。检查混悬液是否有气味变化,在正常荧光灯下目视检查颜色变化,并在光显微镜下检查是否有微生物生长的证据。

结果

环磷酰胺在糖浆和 Ora-Plus 中至少在 4°C 下储存 56 天是稳定的。在室温下,糖浆中环磷酰胺和 Ora-Plus 的保质期分别为 8 天和 3 天。未观察到颜色、气味或微生物生长的变化。

结论

环磷酰胺可以在糖浆或 Ora-Plus 中临时配制,在冷藏条件下至少可储存 2 个月而不会发生明显降解。

相似文献

1
Stability of cyclophosphamide in extemporaneous oral suspensions.
Ann Pharmacother. 2010 Feb;44(2):295-301. doi: 10.1345/aph.1M578. Epub 2010 Jan 26.
2
Stability of extemporaneously prepared cinacalcet oral suspensions.
Am J Health Syst Pharm. 2018 May 1;75(9):e236-e240. doi: 10.2146/ajhp170072.
3
Stability of dolasetron in two oral liquid vehicles.
Am J Health Syst Pharm. 2003 Nov 1;60(21):2242-4. doi: 10.1093/ajhp/60.21.2242.
4
Stability of extemporaneously prepared glycopyrrolate oral suspensions.
Am J Health Syst Pharm. 2011 May 1;68(9):843-5. doi: 10.2146/100247.
5
Stability of zonisamide in extemporaneously compounded oral suspensions.
Am J Health Syst Pharm. 2009 Jun 15;66(12):1105-9. doi: 10.2146/ajhp080250.
6
Stability of an extemporaneous alcohol-free melatonin suspension.
Am J Health Syst Pharm. 2011 Mar 1;68(5):420-3. doi: 10.2146/ajhp100274.
7
Stability of extemporaneously prepared rifaximin oral suspensions.
Am J Health Syst Pharm. 2010 Feb 15;67(4):287-9. doi: 10.2146/ajhp090206.
8
Stability of extemporaneously prepared oxandrolone oral suspensions.
Am J Health Syst Pharm. 2011 Mar 15;68(6):519-21. doi: 10.2146/ajhp100225.
9
Stability of an extemporaneously prepared thalidomide suspension.
Am J Health Syst Pharm. 2012 Jan 1;69(1):56-8. doi: 10.2146/ajhp110105.

本文引用的文献

1
Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS).
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jun 15;877(18-19):1709-15. doi: 10.1016/j.jchromb.2009.04.025. Epub 2009 Apr 24.
2
Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells.
J Pharmacol Sci. 2009 Apr;109(4):473-85. doi: 10.1254/jphs.08173fp.
3
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Microvasc Res. 2007 Sep-Nov;74(2-3):72-84. doi: 10.1016/j.mvr.2007.05.003. Epub 2007 May 18.
5
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.
J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81. doi: 10.1097/01.mph.0000183863.10792.d4.
9
Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags.
Ann Pharmacother. 2003 Dec;37(12):1789-92. doi: 10.1345/aph.1D200.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验